Biotech Stock’s 320% Rally Faces Test With Drug Data Looming

(Bloomberg) -- BioXcel Therapeutics Inc. has been one of Wall Street’s hottest biotech bets as analysts set sky-high price targets and pitched new drugs for brain diseases and tough-to-treat cancer...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.